RecruitingNCT05943002

Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia


Sponsor

German Center for Neurodegenerative Diseases (DZNE)

Enrollment

200 participants

Start Date

Jun 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The PROFA study is an international, multi-centric observational and validation study to assess the patient-reported, psychosocial and economic outcomes of patients with Friedreich Ataxia (FA). Eligible patients will be recruited from six study centers in Germany, Austria and France. Patients will complete a baseline assessment via face-to-face interviews at the study centers and multiple momentary follow-up assessments via a mobile-health app at home daily to monthly for six months. Study results will gain essential and in-depth insights into the daily life of patients with FA.


Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with friedreich ataxia. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(6)

Klinik für Neurologie, Medizinische Universität Innsbruck

Innsbruck, Austria

Paris Brain Institute

Paris, France

Department of Neurology, RWTH Aachen University

Aachen, Germany

German Center for Neuro-degenerative Diseases (DZNE)

Bonn, Germany

Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik

Münich, Germany

Neurologische Klinik und Hertie-Institut für Klinische Hirnforschung, Universitätsklinik Tübingen

Tübingen, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05943002


Related Trials